|
|
Novartis is an early-stage investor with a focus in new therapeutics & platforms, including: medical devices/implants, diagnostics/biomarkers and drug delivery/biopolymers. Novartis regionally invests in the USA/Canada, Europe, Switzerland and Asia/Pacific. The firm currently manages more than $800 million across all of its funds. Novartis Venture Funds makes investments through three investment vehicles: the Novartis Venture Fund, the Novartis Option Fund and the Korea Fund. Novartis anticipates its larger investments will range up to $30 million per company over its life, but these investments can be as little as $100,000 to get started. The venture fund is stage-agnostic and engages in seed investments as well as later-stage investments. The firm will increase its activities to lead or co-lead deals and remains open to participating in larger syndicates. The Novartis Option Fund's to seed innovative startup companies during their earliest stages. The Novartis Option Fund has an initial size of $200M. In 2008, Novartis Venture Funds created the Novartis Korea Venture Fund, a unique commitment to early-stage investing in innovative life sciences companies. In 2011, Novartis increased its portfolio by seven new investments and now comprises over 65 companies, making NVF one of the world's largest and most active corporate life sciences venture funds. Including the commitment of other investors, over $2 billion is invested in NVF portfolio companies.
|
